Hormonal treatment for advancing prostate cancer often can include a chemically castrating drug such as Lupron.  Lupron's activity in men is to reduce the body's production and/or uptake of androgens.  This research finding is frightening in its implications for forcing a choice between the "lesser of two evils." That is, whether to maintain a "normal" level of androgens, known to stimulate prostate cancer growth, or to reduce/remove androgens with a possible increasing likelihood of dementia.